{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:55:55Z","timestamp":1758992155950},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0135232","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T18:02:15Z","timestamp":1439575335000},"page":"e0135232","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production"],"prefix":"10.1371","volume":"10","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"McGivern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley M","family":"Lemon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia J","family":"Reszka-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,8,14]]},"reference":[{"issue":"Suppl 2","key":"ref1","first-page":"13","article-title":"Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience","volume":"23","author":"S Brillanti","year":"1995","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","article-title":"Antiviral action of ribavirin in chronic hepatitis C","volume":"126","author":"JM Pawlotsky","year":"2004","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"S Crotty","year":"2000","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14656560903580001","article-title":"Role of ribavirin in HCV treatment response: now and in the future","volume":"11","author":"MK Jain","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1\u2014D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"JT Witkowski","year":"1972","journal-title":"J Med Chem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"RW Sidwell","year":"1972","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1001\/jama.1983.03330430042027","article-title":"Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults","volume":"249","author":"CB Hall","year":"1983","journal-title":"JAMA"},{"key":"ref8","first-page":"51","article-title":"Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection","volume":"1","author":"FG Hayden","year":"1996","journal-title":"Antivir Ther"},{"key":"ref9","first-page":"20","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"JB McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2125","article-title":"The application and mechanism of action of ribavirin in therapy of hepatitis C","volume":"23","author":"E Thomas","year":"2013","journal-title":"Antivir Chem Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: direct molecular test by using ribavirin","volume":"98","author":"S Crotty","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0042-6822(03)00152-1","article-title":"The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA","volume":"310","author":"S Zhou","year":"2003","journal-title":"Virology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"52471","DOI":"10.1074\/jbc.M308917200","article-title":"Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase","volume":"278","author":"I Bougie","year":"2003","journal-title":"J Biol Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2010.03.037","article-title":"Ribavirin improves early responses to peginterferon through improved interferon signaling","volume":"139","author":"JJ Feld","year":"2010","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.4049\/jimmunol.160.7.3487","article-title":"Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response","volume":"160","author":"Q Ning","year":"1998","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","article-title":"Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile","volume":"30","author":"RC Tam","year":"1999","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.23985","article-title":"Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models","volume":"53","author":"E Thomas","year":"2011","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e27866","DOI":"10.1371\/journal.pone.0027866","article-title":"Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV","volume":"6","author":"NJ Stevenson","year":"2011","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","article-title":"Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response","volume":"46","author":"JJ Feld","year":"2007","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","article-title":"Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C","volume":"63","author":"Y Rotman","year":"2014","journal-title":"Gut"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bpg.2012.09.013","article-title":"Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection","volume":"26","author":"JJ Feld","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/jhep.2002.35529","article-title":"Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin","volume":"36","author":"MW Fried","year":"2002","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"C Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.24744","article-title":"The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C","volume":"55","author":"S Zeuzem","year":"2012","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2893.2012.01624.x","article-title":"Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a\/ribavirin","volume":"19","author":"S Zeuzem","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome","volume":"124","author":"EG Meissner","year":"2014","journal-title":"J Clin Invest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"E Foy","year":"2003","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1073\/pnas.0408824102","article-title":"Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF","volume":"102","author":"K Li","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2012.10.044","article-title":"Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection","volume":"144","author":"DT Lau","year":"2013","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1073\/pnas.1002301107","article-title":"Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection","volume":"107","author":"K Takahashi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2007.10.006","article-title":"Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history","volume":"19","author":"P Fitzgerald-Bocarsly","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","article-title":"IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors","volume":"23","author":"YJ Liu","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4049\/jimmunol.176.1.248","article-title":"Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells","volume":"176","author":"L Chaperot","year":"2006","journal-title":"J Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.chom.2012.08.010","article-title":"Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity","volume":"12","author":"M Dreux","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"M Yi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"T Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"DR McGivern","year":"2014","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"TD Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/labinvest.3700716","article-title":"NOD2: a potential target for regulating liver injury","volume":"88","author":"M Body-Malapel","year":"2008","journal-title":"Lab Invest"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/JVI.01810-10","article-title":"Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection","volume":"85","author":"R Singh","year":"2011","journal-title":"J Virol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"L Chaperot","year":"2001","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/eji.200324531","article-title":"Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts","volume":"34","author":"L Chaperot","year":"2004","journal-title":"Eur J Immunol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e95627","DOI":"10.1371\/journal.pone.0095627","article-title":"Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression","volume":"9","author":"AE Stone","year":"2014","journal-title":"PLoS One"},{"key":"ref47","article-title":"Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations","author":"S Bodeau","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jssc.201301173","article-title":"Quantitation of ribavirin in human plasma and red blood cells using LC-MS\/MS","volume":"37","author":"N Ferreiros","year":"2014","journal-title":"J Sep Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/jmv.21227","article-title":"Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV","volume":"80","author":"F Nicot","year":"2008","journal-title":"J Med Virol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2893.2010.01303.x","article-title":"Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2\/3 infection","volume":"18","author":"C Pedersen","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00281-004-0180-4","article-title":"Plasmacytoid dendritic cell precursors\/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9","volume":"26","author":"T Ito","year":"2005","journal-title":"Springer Semin Immunopathol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.170.9.4465","article-title":"Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells","volume":"170","author":"M Kerkmann","year":"2003","journal-title":"J Immunol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1189\/jlb.72.5.1011","article-title":"CpG-DNA-induced IFN-alpha production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors","volume":"72","author":"R Takauji","year":"2002","journal-title":"J Leukoc Biol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1053\/j.gastro.2009.08.067","article-title":"Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial","volume":"137","author":"ML Shiffman","year":"2009","journal-title":"Gastroenterology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.47.1.124-129.2003","article-title":"Ribavirin quantification in combination treatment of chronic hepatitis C","volume":"47","author":"S Larrat","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3851\/IMP1560","article-title":"Plasma\/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response","volume":"15","author":"L Baiocchi","year":"2010","journal-title":"Antivir Ther"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1128\/JVI.02280-08","article-title":"Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance","volume":"83","author":"KD Ibarra","year":"2009","journal-title":"J Virol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350801300401","article-title":"Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients","volume":"13","author":"M Maynard","year":"2008","journal-title":"Antivir Ther"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2893.2008.01004.x","article-title":"Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin","volume":"15","author":"H Toyoda","year":"2008","journal-title":"J Viral Hepat"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13238-012-2104-8","article-title":"Regulation of TLR7\/9 signaling in plasmacytoid dendritic cells","volume":"4","author":"M Bao","year":"2013","journal-title":"Protein Cell"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0014-5793(98)01514-2","article-title":"Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7","volume":"441","author":"M Sato","year":"1998","journal-title":"FEBS Lett"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.1128\/JVI.00280-11","article-title":"Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis","volume":"85","author":"RP Kannan","year":"2011","journal-title":"J Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0168-8278(98)80052-4","article-title":"Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?","volume":"29","author":"J McHutchison","year":"1998","journal-title":"J Hepatol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2014.09.013","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"62","author":"JJ Feld","year":"2015","journal-title":"J Hepatol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2013.02.008","article-title":"A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment","volume":"59","author":"E Lawitz","year":"2013","journal-title":"J Hepatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","author":"E Lawitz","year":"2013","journal-title":"Antiviral Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0135232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T05:29:08Z","timestamp":1691904548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0135232"}},"subtitle":[],"editor":[{"given":"Wenzhe","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,14]]},"references-count":71,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0135232","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,14]]}}}